Last reviewed · How we verify

Individual ATG — Competitive Intelligence Brief

Individual ATG (Individual ATG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antithymocyte globulin (immunosuppressant). Area: Immunology.

marketed Polyclonal antithymocyte globulin (immunosuppressant) T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Individual ATG (Individual ATG) — The First Affiliated Hospital of Soochow University. ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Individual ATG TARGET Individual ATG The First Affiliated Hospital of Soochow University marketed Polyclonal antithymocyte globulin (immunosuppressant) T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antithymocyte globulin (immunosuppressant) class)

  1. The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Individual ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/individual-atg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: